Janus Kinase Inhibitors

Janus Kinase Inhibitor

Arthritis, Rheumatoid

<section class="Section" data-sectioncode="34089-3"><a name="section-9"></a><h1>11 DESCRIPTION</h1>RINVOQ and RINVOQ LQ are formulated with upadacitinib, a JAK inhibitor. Upadacitinib has the following chemical name: (3S,4R)-3-Ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide hydrate (2:1). The strength of upadacitinib is based on anhydrous upadacitinib. The solubility of upadacitinib in water is 38 to less than 0.2 mg/mL across a pH range of 2 to 9 at 37 oC. Upadacitinib has a molecular weight of 389.38 g/mol and a molecular formula of C17H19F3N6O • ½ H2O. The chemical structure of upadacitinib is: <img alt="upadacitinib-chem-structure" src="rinvoq-01.jpg"/>RINVOQ 15 mg extended-release tablets for oral administration are purple, biconvex oblong, with dimensions of 14 x 8 mm, and debossed with ‘a15’ on one side. Each tablet contains the following inactive ingredients: colloidal silicon dioxide, ferrosoferric oxide, hypromellose, iron oxide red, magnesium stearate, mannitol, microcrystalline cellulose, polyvinyl alcohol, polyethylene glycol, talc, tartaric acid and titanium dioxide. RINVOQ 30 mg extended-release tablets for oral administration are red, biconvex oblong, with dimensions of 14 x 8 mm, and debossed with ‘a30’ on one side. Each tablet contains the following inactive ingredients: colloidal silicon dioxide, hypromellose, iron oxide red, magnesium stearate, mannitol, microcrystalline cellulose, polyvinyl alcohol, polyethylene glycol, talc, tartaric acid and titanium dioxide. RINVOQ 45 mg extended-release tablets for oral administration are yellow to mottled yellow, biconvex oblong, with dimensions of 14 x 8 mm, and debossed with ‘a45’ on one side. Each tablet contains the following inactive ingredients: colloidal silicon dioxide, hypromellose, iron oxide yellow, iron oxide red, magnesium stearate, mannitol, microcrystalline cellulose, polyvinyl alcohol, polyethylene glycol, talc, tartaric acid and titanium dioxide.RINVOQ LQ oral solution for oral administration is a 1 mg/mL clear, colorless to light yellow solution. Each 1 mL RINVOQ LQ contains 1 mg of upadacitinib as free base (equivalent to 1.02 mg upadacitinib hemihydrate) and the following inactive ingredients: citric acid anhydrous, purified water, sodium benzoate, sodium citrate dihydrate, and sucralose. </section>

Rinvoq

upadacitinib

24 HR upadacitinib 15 MG Extended Release Oral Tablet

24 HR upadacitinib 15 MG Extended Release Oral Tablet [Rinvoq]

24 HR upadacitinib 30 MG Extended Release Oral Tablet

24 HR upadacitinib 30 MG Extended Release Oral Tablet [Rinvoq]

24 HR upadacitinib 45 MG Extended Release Oral Tablet

24 HR upadacitinib 45 MG Extended Release Oral Tablet [Rinvoq]

upadacitinib 1 MG/ML Oral Solution

upadacitinib 1 MG/ML Oral Solution [Rinvoq]

University of Missouri Specialty Pharmacy

Actemra

Afinitor

Alecensa

Aranesp

Ayvakit

Benlysta

Braftovi

Bosulif

Cabometyx

Cotellic

Cosentyx

Enbrel

Erivedge

Erleada

Esbriet

Farydak

Fasenra

Gavreto

Ibrance

Ilaris

Imbruvica

Imfinzi

Inlyta

Inqovi

Jakafi

Koselugo

Lonsurf

Lorbrena

Lynparza

Mayvret

Mekinist

Nexavar

Nplate

Nubeqa

Ocrevus

Ofev

Olumiant

Onureg

Piqray

Promacta

Qinlock

Retacrit

Rubraca

Somatuline

Stelara

Stivarga

Sutent

Tarbrecta

Tafinlar

Tagrisso

Tarceva

Targretin

Tasigna

Tecfidera

Temodar

Tykerb

Venclexta

Vitravki

Votrient

Xolair

Xpovio

Xtandi

Yonsa

Zejula

Zelboraf

Zeposia

Zydelig

Zykadia

Rinvoq | University of Missouri Specialty Pharmacy

Which health plans does University of Missouri Specialty Pharmacy have contracts with?

Does University of Missouri Specialty Pharmacy work closely with Rinvoq and AbbVie Inc.?

Does University of Missouri Specialty Pharmacy offer services for Rinvoq patients?

What conditions does University of Missouri Specialty Pharmacy support?

How does University of Missouri Specialty Pharmacy help with insurance?